FindTrial
Sign In

Incidence, patterns, risk factors, and management of immediate hypersensitivity reactions in gynecologic cancer patients receiving paclitaxel -based chemotherapy

Incidence, patterns, risk factors, and management of immediate hypersensitivity reactions in gynecologic cancer patients receiving paclitaxel -based chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20200220001
Enrollment
Unknown
Registered
2020-02-20
Start date
2019-02-14
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with cancer Adverse drug reactions&#44

Interventions

Gynecologic cancer patients receiving paclitaxel &#45
based chemotherapy
Supportive Care
Gynecologic cancer

Sponsors

no
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 84 Years

Inclusion criteria

Inclusion criteria: Diagnosis with gynecologic malignancy and received of paclitaxel-based chemotherapy between January 2012 and December 2017.

Exclusion criteria

Exclusion criteria: HSRs more than one hour after starting paclitaxel administration or had incomplete medical records

Design outcomes

Primary

MeasureTime frame
Hypersensitivity 6 years Incidence—

Secondary

MeasureTime frame
Risk factor 6 years Number of event—

Contacts

Public ContactPiyarat Pimsi

Faculty of Pharmacy, Silpakorn University

pimsi_p@su.ac.th0938256149

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026